Alsertib

Developed for: non-Hodgkin lymphoma
Investigated by: Eric Bernicker, MD · Millennium Pharmaceuticals, Inc. · The Methodist Hospital Research Institute

today NCT02780011 · Ph 1

201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02780011	Dec 2015 → Sep 2018	non-Hodgkin lymphoma	Eric Bernicker, MD	Withdrawn	No outcome recorded Stop: Business

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Alsertib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02780011 ↗
Action	Inhibit	“Aurora A kinase inhibitor” NCT02780011 ↗
Route	Oral	“will be orally administered” NCT02780011 ↗